Sichuan Kelun Pharmaceutical Co., Ltd.

The company was founded in 1996 and has now formed a “product” structure operating platform composed of Colon Pharmaceutical, Twining Biotech, and Colon Botai, with a total market value of over 100 billion dollars. In 2018, Colon was awarded the “Single Champion Demonstration Enterprise in the Manufacturing Industry” for its global advantages in high-volume injections. In 2023, Colon ranked among the top three in China's pharmaceutical manufacturing industry. The company is mainly engaged in R&D, production and sales of 24 types of pharmaceuticals, such as high-volume injections (infusions), small-volume injections (including dispensed powder needles and freeze-dried powder needles), tablets, capsules, granules, oral solutions, peritoneal dialysis solutions, APIs, etc., as well as antibiotic intermediates, medical devices and other products. The company's main products cover anti-tumor, cardiovascular, anesthetic and analgesic, psychiatric, anti-pathogenic microorganisms, nutritional infusions, respiratory, anti-osteoporosis, male specialty, diabetes, hydroelectrolyte balance, diagnostic imaging, hepatitis B and other diseases. Corporate honors: National Technological Innovation Demonstration Enterprise, Industrial Brand Cultivation Demonstration Enterprise, National Science and Technology Progress Award, etc.